Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05531526). This is a study registration, not published results. Lead sponsor: AriBio Co., Ltd.. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1535 participants (ACTUAL). Conditions: Alzheimer Disease. Interventions: DRUG: AR1001; DRUG: Placebo. Primary outcome measures: Change from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Overall Population) , Baseline to Week 52; Change from Baseline in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) (Monotherapy Population) , Baseline to Week 52. Brief summary: This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.